Maze Therapeutics (MAZE) Tops Q1 EPS by 13c
Tweet
Share
E-mailGet Alerts MAZE Hot Sheet
Join SI Premium – FREE
Maze Therapeutics (NASDAQ: MAZE) reported Q1 EPS of ($0.45), $0.13 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $20 million.
For earnings history and earnings-related data on Maze Therapeutics (MAZE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UGI shares spike on reported KKR bid for the company
- Piper Sandler Downgrades Weave Communications Inc (WEAV) to Neutral
- WaterBridge Infrastructure (WBI) PT Raised to $40 at Raymond James
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
